TVTX: Guggenheim Raises Target
Guggenheim analyst Vamil Divan maintains a Buy rating on Travere Therapeutics and raises the price target to $65
Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ: TVTX ) with a Buy and raises the price target from $56 to $65.